| 効果 | なし |
| 試験方法 | コホート法 |
| 試験期間 | 6+ ヶ月 |
| 被験者数 | 50 |
| 性別 | 女性 |
| 年齢 | 18-29, 30-44 |
| 体型 | 肥満 |
Supplementation of myo-inositol by itself at 2g daily for a period of six months in women with PCOS was associated with improvements in diastolic blood pressure. The combination with D-chiroinositol was the same at a lower dose (550mg and 13.8mg, respectively) when measured at six months, but seemed to act faster as inositol at 2g required six months to be fully effective.
Effects Of Inositol On Ovarian Function And Metabolic Factors In Women With PCOS: A Randomized Double Blind Placebo-controlled Trial
| 効果 | 減少 |
| 試験方法 | 二重盲検法 |
| 試験期間 | 1-6 ヶ月 |
| 被験者数 | 281 |
| 性別 | 女性 |
| 年齢 | 18-29, 30-44 |
| 体型 | 肥満 |
200mg of inositol daily (in two divided doses of 100mg) for a period of 12 weeks in women with PCOS was ineffective in improving the glucose metabolic markers yet was effective in reducing body weight and improving fertility.
One-year Effects Of Myo-inositol Supplementation In Postmenopausal Women With Metabolic Syndrome
| 効果 | なし |
| 試験方法 | 二重盲検法 |
| 試験期間 | 6+ ヶ月 |
| 被験者数 | 80 |
| 性別 | 女性 |
| 年齢 | 45-64, 65+ |
| 体型 | 肥満 |
Supplementation of myo-inositol at 2g twice daily for the course of one year in postmenopausal women with metabolic syndrome was associated with improvements on all metabolic parameters measured (cardiovascular health and glucose metabolism) although no influence on weight was noted.
Inositol Administration Reduces Oxidative Stress In Erythrocytes Of Patients With Polycystic Ovary Syndrome
| 効果 | 減少 |
| 試験方法 | 二重盲検法 |
| 試験期間 | 1-6 ヶ月 |
| 被験者数 | 26 |
| 性別 | 女性 |
| 年齢 | 18-29 |
| 体型 | 平均 |
Supplementation of 1,200mg Myo-inositol daily for a period of 12 weeks in normal weight women (22-30yrs) with PCOS was able to decrease weight (−1.83+/-1.86kg, very unreliable in magnitude) and improved markers of glucose and androgen metabolism. An improvement in oxidative biomarkers was also noted (GSH in red blood cells).
Randomized, Double Blind Placebo-controlled Trial: Effects Of Myo-inositol On Ovarian Function And Metabolic Factors In Women With PCOS
| 効果 | 減少 |
| 試験方法 | 二重盲検法 |
| 試験期間 | 1-6 ヶ月 |
| 被験者数 | 92 |
| 性別 | 女性 |
| 年齢 | 18-29, 30-44 |
| 体型 | 肥満, 肥満, 平均 |
4g of inositol daily for a period of 16 weeks in women with PCOS was ineffective in improving parameters of insulin sensitivity while it was sufficient to improve biomarkers of steroid metabolism and fertility. Weight was decreased in all subjects who were not morbidly obese.
Differential Insulin Response To Myo-inositol Administration In Obese Polycystic Ovary Syndrome Patients
| 効果 | 減少 |
| 試験方法 | コホート法 |
| 試験期間 | 1-6 ヶ月 |
| 被験者数 | 42 |
| 性別 | 女性 |
| 年齢 | 18-29, 30-44 |
| 体型 | 肥満 |
Supplementation of 2,000mg inositol (INOFERT) once daily for eight weeks in obese women with PCOS was able to improve insulin sensitivity and other biomarkers of glucose metabolism only in those with higher circulating insulin concentrations.
No placebo control was used in this study.
Myo-inositol Treatment Increases Serum Plasmalogens And Decreases Small Dense LDL, Particularly In Hyperlipidemic Subjects With Metabolic Syndrome
| 効果 | なし |
| 試験方法 | コホート法 |
| 試験期間 | 1-2 週間 |
| 被験者数 | 17 |
| 性別 | 男女 |
| 年齢 | 30-44, 45-64 |
| 体型 | 肥満 |
スポンサーリンクTwo weeks supplementation of _myo_-inositol at 5g (first week) and 10g (second week) was able to increase circulating levels of choline plasmalogen, which is thought to be the reason behind a reduction in LDL-C. These changes were not present in persons without metabolic syndrome.